489 related articles for article (PubMed ID: 33220589)
41. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
Moshaver B; Wouters RF; Kelder A; Ossenkoppele GJ; Westra GAH; Kwidama Z; Rutten AR; Kaspers GJL; Zweegman S; Cloos J; Schuurhuis GJ
Leuk Res; 2019 Jun; 81():27-34. PubMed ID: 31002948
[TBL] [Abstract][Full Text] [Related]
42. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Kikushige Y; Miyamoto T
Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
44. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
Eisenwort G; Sadovnik I; Keller A; Ivanov D; Peter B; Berger D; Stefanzl G; Bauer K; Slavnitsch K; Greiner G; Gleixner KV; Sperr WR; Willmann M; Sill H; Bettelheim P; Geissler K; Deininger M; Rülicke T; Valent P
Leukemia; 2021 Nov; 35(11):3176-3187. PubMed ID: 33785864
[TBL] [Abstract][Full Text] [Related]
45. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
46. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
47. Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.
Yanagisawa B; Ghiaur G; Smith BD; Jones RJ
Exp Hematol; 2016 Dec; 44(12):1130-1137. PubMed ID: 27693555
[TBL] [Abstract][Full Text] [Related]
48. [Changes of Leukemia Stem Cells in Acute Myeloid Leukemia before and after Treatment].
Lv JT; Yang ZG; Guang YH; Lin ZS; Xiao XX; Liu D; Shi M; Wang WS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):658-664. PubMed ID: 29950200
[TBL] [Abstract][Full Text] [Related]
49. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Ngai LL; Ma CY; Maguire O; Do AD; Robert A; Logan AC; Griffiths EA; Nemeth MJ; Green C; Pourmohamad T; van Kuijk BJ; Snel AN; Kwidama ZW; Venniker-Punt B; Cooper J; Manz MG; Gjertsen BT; Smit L; Ossenkoppele GJ; Janssen JJWM; Cloos J; Sumiyoshi T
Eur J Haematol; 2021 Sep; 107(3):343-353. PubMed ID: 34053123
[TBL] [Abstract][Full Text] [Related]
50. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
[TBL] [Abstract][Full Text] [Related]
51. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34
Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM; Mims A; Brooks C; Dorrance A; Walker A; Blum W; Byrd JC; Lozanski G; Vasu S; Muthusamy N
Haematologica; 2018 Aug; 103(8):1288-1297. PubMed ID: 29773600
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B
Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721
[TBL] [Abstract][Full Text] [Related]
53. [Acute myeloid leukemia stem cells from genomic and immunological perspectives].
Goyama S
Rinsho Ketsueki; 2020; 61(9):1130-1137. PubMed ID: 33162508
[TBL] [Abstract][Full Text] [Related]
54. Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance.
Zhi L; Wang M; Rao Q; Yu F; Mi Y; Wang J
Cancer Lett; 2010 Oct; 296(1):65-73. PubMed ID: 20444543
[TBL] [Abstract][Full Text] [Related]
55. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
56. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
[TBL] [Abstract][Full Text] [Related]
57. [Progress in the studies of acute myelogenous leukemia stem cell].
Cui JW; Zhang XM; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558
[TBL] [Abstract][Full Text] [Related]
58. The cell of origin and the leukemia stem cell in acute myeloid leukemia.
Chopra M; Bohlander SK
Genes Chromosomes Cancer; 2019 Dec; 58(12):850-858. PubMed ID: 31471945
[TBL] [Abstract][Full Text] [Related]
59. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).
Mitchell K; Steidl U
Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31451539
[TBL] [Abstract][Full Text] [Related]
60. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
